GGrantIndex
← Leaderboards

Ellen R. Wald

Children'S Hosp Pittsburgh/Upmc Hlth Sys

Google Scholar ↗PubMed ↗ORCID ↗
$8,036,977
Attributed
$11,114,628
Total exposure
10
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY2006–25
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,678,878 · 8
AHRQ$435,750 · 2

By mechanism

U01$4,919,729 · 1
R01$4,339,245 · 2
R21$1,855,654 · 6
M01$0 · 1

Top collaborators

Most similar at Children'S Hosp Pittsburgh/Upmc Hlth Sys

Same institution · by research overlap

Others in their field

Top investigators on “Child”

Research focus

ChildAcuteAntibioticsAntimicrobialSinusitisStreptococcus PneumoniaeSymptomsPathogenHaemophilus InfluenzaeBacterial InfectionsBaseRespiratoryMoraxella (Branhamella) CatarrhalisUpper Respiratory InfectionsDiagnosisEnrollmentViralOtitis MediaRespiratory SystemDiagnosticAcute Bacterial SinusitisInfection12 Year OldSampling

Grant awards (24)

Identifying the burden of hospitalization due to Rhinovirus (RV) in children and mechanisms of pathogenesis using airway molecular profiling$779,170
R01 · FY2025 · AI · contact PI
Feasibility of a study to determine the incidence, spectrum, course and outcome of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) in a diverse group of children$246,884
R21 · FY2025 · MH · contact PI
Transcriptomic and Genetic Differences of Group A Streptococcus in Humans: Acute Infection versus Carriage$208,598
R21 · FY2020 · AI
Efficacy of Antibiotics in Children with Acute Sinusitis: Which Subgroups Benefit?$971,785
U01 · FY2019 · AI
Nasal cytokine responses in children with viral upper respiratory infection$309,167
R21 · FY2019 · AI · contact PI
Transcriptomic and Genetic Differences of Group A Streptococcus in Humans: Acute Infection versus Carriage$247,805
R21 · FY2019 · AI
Efficacy of Antibiotics in Children with Acute Sinusitis: Which Subgroups Benefit?$975,370
U01 · FY2018 · AI
Efficacy of Antibiotics in Children with Acute Sinusitis: Which Subgroups Benefit?$975,370
U01 · FY2017 · AI
Efficacy of Antibiotics in Children with Acute Sinusitis: Which Subgroups Benefit?$975,370
U01 · FY2016 · AI
Sinusitis in Children and the Nasopharyngeal Microbiome$684,241
R01 · FY2016 · AI · contact PI
Efficacy of Antibiotics in Children with Acute Sinusitis: Which Subgroups Benefit?$1,021,834
U01 · FY2015 · AI
Sinusitis in Children and the Nasopharyngeal Microbiome$700,781
R01 · FY2015 · AI · contact PI
Sinusitis in Children and the Nasopharyngeal Microbiome$718,967
R01 · FY2014 · AI · contact PI
Sinusitis in Children and the Nasopharyngeal Microbiome$691,569
R01 · FY2013 · AI · contact PI
An interactive web-based intervention to achieve healthy weight in young children$179,843
R21 · FY2013 · HD · contact PI
Sinusitis in Children and the Nasopharyngeal Microbiome$764,517
R01 · FY2012 · AI · contact PI
An interactive web-based intervention to achieve healthy weight in young children$227,607
R21 · FY2012 · HD · contact PI
Treatment of children with obesity in primary care$220,500
R21 · FY2007 · HS · contact PI
Treatment of children with obesity in primary care$215,250
R21 · FY2006 · HS · contact PI
A Pediatric PBRN (Pediatric PitNet) and a Pilot Project$0
R21 · FY2003 · HS
A Pediatric PBRN (Pediatric PitNet) and a Pilot Project$0
R21 · FY2002 · HS
PHARMACOKINETICS OF ORAL GANCICLOVIR IN PEDIATRIC PATIENTS$0
M01 · FY2002 · RR
PHARMACOKINETICS OF ORAL GANCICLOVIR IN PEDIATRIC PATIENTS$0
M01 · FY2001 · RR
PHARMACOKINETICS OF ORAL GANCICLOVIR IN PEDIATRIC PATIENTS$0
M01 · FY2000 · RR